<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell J</journal-id><journal-id journal-id-type="iso-abbrev">Cell J</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>Cell Journal (Yakhteh)</journal-title></journal-title-group><issn pub-type="ppub">2228-5806</issn><issn pub-type="epub">2228-5814</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">36043408</article-id><article-id pub-id-type="pmc">PMC9428476</article-id><article-id pub-id-type="other">Cell-J-24-403</article-id><article-id pub-id-type="doi">10.22074/cellj.2022.7835</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Genetics</subject><subject>Immunology</subject></subj-group></subj-group></article-categories><title-group><article-title>Study of The Correlation between miR-106a, miR-125b, and
miR-330 on Multiple Sclerosis Patients by Targeting TNFSF4
and SP1 in NF-&#x0043a;b/TNF-&#x003b1; Pathway: A Case-Control Study </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hadi</surname><given-names>Nasrin</given-names></name><degrees>M.Sc</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Seifati</surname><given-names>Seyed Morteza</given-names></name><degrees>Ph.D</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Nateghi</surname><given-names>Behnaz</given-names></name><degrees>M.Sc</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Ravaghi</surname><given-names>Parisa</given-names></name><degrees>M.Sc</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Khosravian</surname><given-names>Farinaz</given-names></name><degrees>M.Sc</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Namazi</surname><given-names>Faezeh</given-names></name><degrees>M.Sc</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Fotouhi Firouzabad</surname><given-names>Maryam</given-names></name><degrees>M.Sc</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Shaygannejad</surname><given-names>Vahid</given-names></name><degrees>M.D</degrees><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Mansoor</given-names></name><degrees>Ph.D.</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="A1"><label>1</label>Medical Biotechnology Research Center, Ashkezar Branch, Islamic Azad University, Ashkezar, Yazd, Iran</aff><aff id="A2"><label>2</label>Medical Genetics Research Center of Genome, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="A3"><label>3</label>Cellular, Molecular, and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="A4"><label>4</label>Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran</aff><aff id="A5"><label>5</label>Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="A6"><label>6</label>Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</aff></contrib-group><author-notes><corresp id="cor1">
<label>*Corresponding Address:</label>
<addr-line>P.O.Box: 81746-73461</addr-line>
<addr-line>Department of Genetics and Molecular Biology</addr-line>
<addr-line>School of Medicine</addr-line>
<institution>Isfahan University of
Medical Sciences</institution>
<addr-line>Isfahan</addr-line>
<country>Iran</country>
Email:<email>m_salehi@med.mui.ac.ir</email>
</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>27</day><month>7</month><year>2022</year></pub-date><volume>24</volume><issue>7</issue><fpage>403</fpage><lpage>409</lpage><history><date date-type="received"><day>21</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2022</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium,
with the exception of commercial purposes, is permitted provided the original work is properly cited.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0) License, which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited. </license-p></license></permissions><abstract><sec><title>Objective</title><p> Multiple sclerosis (MS) is a complex multifactorial neuro-inflammatory disorder. This complexity arises from
the evidence suggesting that MS is developed by interacting with environmental and genetic factors. This study aimed
to evaluate the miR-106a, miR-125b, and miR330- expression levels in relapsing-remitting multiple sclerosis (RRMS)
patients. The miRNAs' impact on TNFSF4 and Sp1 genes through the NF-&#x0043a;B/TNF-&#x003b1; signaling pathway was analyzed
by measuring the expression levels in case and controls.
</p></sec><sec><title>Materials and Methods</title><p> In this in silico-experimental study, we evaluated the association of miR-106a, miR-
125b, and miR330- with TNFSF4 and SP1 gene expression levels in 60 RRMS patients and 30 healthy controls by
real-time polymerase chain reaction (PCR).
</p></sec><sec><title>Results</title><p> The expression levels of miR-330, miR-106a, and miR125-b in blood samples of RRMS patients were
predominantly reduced. The expression of TNFSF4 in patients demonstrated a significant enhancement, in contrast to
the diminishing Sp1 gene expression level in controls.
</p></sec><sec><title>Conclusion</title><p>Our findings indicated an association between miR-106a and miR-330 and miR125-b expression
and RRMS in our study population. Our data suggested that the miR106-a, miR125-b, and mir330- expression are
correlated with TNFSF4 and Sp1 gene expression levels.</p></sec></abstract><kwd-group><kwd>Biomarker</kwd><kwd>microRNA</kwd><kwd>Multiple Sclerosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Hadi N, Seifati SM, Nateghi B, Ravaghi P, Khosravian F, Namazi F, Fotouhi Firouzabad M, Shaygannejad V, Salehi M. Study of the correlation between
miR-106a, miR-125b, and miR-330 on multiple sclerosis patients by targeting TNFSF4 and SP1 in NF-&#x0043a;b/TNF-&#x003b1; pathway: a case-control study. Cell J. 2022; 24(7):
403-409. doi: 10.22074/cellj.2022.7835.
This open-access article has been published under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0).</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Multiple sclerosis (MS) disorders are developed due
to chronic inflammation of the central nervous system
(CNS) and can increase focal lesions in the white matter
of the spinal cord and brain (<xref rid="B1" ref-type="bibr">1</xref>). Clinical studies have
shown that MS affects women 2-fold higher than men,
and the progressive phase was between 5 and 35 years
after the first onset (<xref rid="B2" ref-type="bibr">2</xref>). Relapsing-remitting MS (RRMS)
is the typical primary type of MS and accounts for about
85% of MS patients (<xref rid="B3" ref-type="bibr">3</xref>). There is no standardized method
of how to pursue MS patients to detect disease activity
(<xref rid="B4" ref-type="bibr">4</xref>). Although MS&#x02019;s exact etiology remains enigmatic, the
identification of genetic variations affecting MS disease
development has grown in the last few years (<xref rid="B5" ref-type="bibr">5</xref>).
</p><p>Immense evidence has indicated that tumor necrosis
factor alpha (TNF-&#x003b1;) plays a pivotal role in MS
development (<xref rid="B6" ref-type="bibr">6</xref>-<xref rid="B8" ref-type="bibr">8</xref>). Consecutive TNF-&#x003b1; expression could
induce chronic inflammatory demyelinating disorder,
synaptic instability in the brain, and subsequently sensory
and cognitive damage (<xref rid="B9" ref-type="bibr">9</xref>). It has been demonstrated that
the damaging role of TNF-&#x003b1; in MS might significantly
relate to its transmembrane receptors tumor necrosis factor
receptor type II (TNF-RII) or receptors, tumor necrosis
factor (TNFR-I) (<xref rid="B10" ref-type="bibr">10</xref>). TNF receptors are present at the
cell surface as monomers, while the monomers&#x02019; ligandinduced homodimerization activates TNF-&#x003b1; signaling.
OX40L is recognized as a ligand for OX40, also known
as tumor necrosis factor ligand superfamily member 4
(TNFSF4) and CD252 (Cluster of differentiation 252),
and is a type II transmembrane protein that might have
a pivotal role in the differentiation and stimulation of
T-cells. TNFSF4 is mainly expressed on the surface of
T-cell antigen-presenting cell (APC) cells (<xref rid="B11" ref-type="bibr">11</xref>). The
encoded protein of this gene is primarily expressed on
activated CD4+ and CD8+ T-cells and various B-cells,
microglia, vascular endothelial cells, and dendritic cells (<xref rid="B12" ref-type="bibr">12</xref>). The encoded protein is involved in APC interactions
and facilitates the adhesion of T-cells to endothelial
cells. Interaction between TNFSF4 and CD4+ T-cells
by TNFSF4 stimulates nuclear factor-kappa B (NF-&#x003ba;B)
through TNF-R related TRAF1 and TRAF2. Besides, this
signaling pathway is related to several immune functional
activities, which include the intensification of Th2
responses and the production of Th2 and Th1 cytokines
(<xref rid="B13" ref-type="bibr">13</xref>).</p><p>Sp1 is a transcription factor that binds to many promoters.
Moreover, SP1 could involve in many processes such as
apoptosis and immune responses. It has been proved that
there is a relationship between Sp1 expression and the
activity of the inflammatory cytokine TNF (<xref rid="B14" ref-type="bibr">14</xref>). Sp1 sites
are frequently observed in NF-&#x003ba;B related genes, which
can activate specific promoters in NF-&#x003ba;B over its binding
sites. Sp1 acts through NF-&#x003ba;B by activating the NF-&#x003ba;B
promoter sites (<xref rid="B15" ref-type="bibr">15</xref>).
</p><p>The association of miRNA with components of
the RNA-induced silencing complex (RISC) results
in the degradation or translational repression and/or
destabilization of their relevant mRNA. It occurs through
miRNA binding to the 3&#x02032;-untranslated region (UTR)
of target genes (<xref rid="B16" ref-type="bibr">16</xref>). Growing evidence has shown the
abnormal miRNA activity in CNS glial cells of patients
with MS and peripheral blood immune cells compared
with normal individuals, suggesting that miRNA
expression could be correlated with MS pathogenesis and
immunological features (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Honardoost et al. (<xref rid="B18" ref-type="bibr">18</xref>) have proposed that miR-106a
probably has an inductive function in Th17 differentiation.
Sanctuary et al. (<xref rid="B19" ref-type="bibr">19</xref>) have revealed that Mir-106a may have
a crucial function in inflammatory bowel disease through
the TNF-&#x003b1; pathway. Also, the biological role of miR330-5p has been offered in some cells and cancers (<xref rid="B20" ref-type="bibr">20</xref>).
According to Mao et al. (<xref rid="B21" ref-type="bibr">21</xref>) study on prostate cancer cells,
microRNA-330 suppresses cell motility by decreasing the
expression of Sp1, which plays the role of a transcription
factor through the TNF-&#x003b1; pathway. Furthermore, miR125b was demonstrated to bind the 3&#x02032;UTR of TNF-&#x003b1;;
therefore, MicroRNAs could reduce the expression of
TNF-&#x003b1; in the innate immune response pathway. In this
study, we examined whether the dysregulated expression
of miR-106a, miR-125b, and mir-330 can be considered
a diagnostic biomarker in RRMS patients with recurrent
disease symptoms two months after relapse. This study
evaluated the correlation of miRNAs with the TNFSF4
and SP1 mRNA and its pathogenicity by examining the
expression levels of miR-106a and miR-125b, and miR330 in normal and MS samples.</p></sec><sec sec-type="materials-methods"><title>Materials and Methods</title><sec><title>Ethical Issue</title><p>All experimental procedures were approved by the Ethic
Committee of the Isfahan University of Medical Sciences
(289271) . </p></sec><sec><title>miRNA prediction</title><p>In this in silico-experimental study, we collected lists of
microRNA target genes using miRWalk (<xref rid="B22" ref-type="bibr">22</xref>) and a list of
gene-disease association export of DisGeNET (<xref rid="B23" ref-type="bibr">23</xref>). We
chose genes that overlapped between these lists. These
genes were studied in several databases for data mining.
In this search, we evaluated Reactome (<xref rid="B24" ref-type="bibr">24</xref>), DAVID,
STRING, and KEGG analysis. Interactions between
genes, microRNAs, and pathways are illustrated in the
designed network using Cytoscape software (<xref rid="B25" ref-type="bibr">25</xref>). </p></sec><sec><title>Patients and controls</title><p>The Informed consent was taken from all subjects
before sample collection. Briefly, we collected 4mL
of blood from 90 participants (both male and female),
including 60 RRMS patients and 30 healthy subjects.
Overall, 30 healthy controls were recruited from Kashani
Hospital (Isfahan, Iran), and 60 patients with RRMS were
divided into two groups, including 30 who were recurrent
and 30 who had recurrences for at least two months.
Based on medical examinations, the healthy participants
had no family history of autoimmune disease. The RRMS
patients were diagnosed by a specific neurologist based on
McDonald&#x02019;s criteria (<xref rid="B26" ref-type="bibr">26</xref>). 32 of these patients had solely
received interferon (IFN)-&#x003b2; treatment two months before
sampling, and the rest had not received any treatments.
In the next step, we collected.</p></sec><sec><title>Preparing peripheral blood human mononuclear cells
from blood</title><p>Blood samples were isolated through a gradient of density
Lymphoprep Peripheral Blood Human Mononuclear
Cells (PBMCs, Bio Sera, USA). The cells remained in an
intermediate phase after centrifugation, although other cells
were deposited. In the next step, we gradually diluted the
lymphoprep solution in a falcon tube with physiological
saline at a ratio of 1:1, and then the solution was centrifuged
at 800 g for 30 minutes (<xref rid="B27" ref-type="bibr">27</xref>). Afterward, Peripheral Blood
Human Mononuclear Cells were transferred into a 2 ml
RNAase-free microtube from the middle phase. </p></sec><sec><title>Evaluating the expression of genes and MicroRNAs</title><p>RNA extraction from PBMCs was conducted by TRIzol reagent (Invitrogen, USA). The purity
of the RNA was evaluated by a NanoDrop spectrometer. Furthermore, cDNA was prepared by a
cDNA Synthesis Kit (TaKaRa, Japan). Additionally, the miRNA synthesis of RNA was done
using a standard kit (Pars Genome, Tehran, Iran).<italic> U6</italic> was selected as the
housekeeping gene for the normalization of the miRNAs data. Also, For the normalization of
genes, <italic>GAPDH</italic> was considered a reference gene. The quantitative real-time
polymerase chain reaction (qPCR) was accomplished by the Rotor-Gene 6000 (Corbett Life
Science, Australia), and the repetition of samples was duplicated. Moreover, the amount of
cycle threshold of real-time was determined by 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> methods. Primers
purchased from micro-gene (Korea) are indicated in Table 1.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>The primer genes list</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="3" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">Genes</th><th rowspan="1" colspan="1">Primer sequence (5&#x01ffd;&#x02192;3&#x01ffd;)</th><th rowspan="1" colspan="1">Temperature (&#x000b0;C)</th></tr><tr><th colspan="3" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>SP1</italic>
</td><td rowspan="1" colspan="1">F: TTG AAA AAG GAG TTG GTG GC</td><td rowspan="1" colspan="1">60</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">R: TGC TGG TTC TGT AAG TTG GG</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>TNFSF4</italic>
</td><td rowspan="1" colspan="1">F: GAAGAAGGTCAGGTCTGTCAAC</td><td rowspan="1" colspan="1">58</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">R: AATCAGTTCTCCGCCATTCAC</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>GAPDH</italic>
</td><td rowspan="1" colspan="1">F: TGCCGCCTGGAGAAACC</td><td rowspan="1" colspan="1">60</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">R: TGAAGTCGCAGGAGACAACC</td><td rowspan="1" colspan="1"/></tr><tr><th colspan="3" rowspan="1">
<hr/>
</th></tr></tbody></table></table-wrap></sec><sec><title>Statistical analysis</title><p>Statistical analysis
The GraphPad Prism Ver.9 (San Diego, USA) was
applied to analyze the real time polymerase chain reaction
(PCR) results. The Kolmogorov-Smirnov test was used
to evaluate the normal distribution of the data. The
one-way ANOVA test was used to analyze expression
levels between two case and control groups. P&#x0003c;0.05 was
considered statistically significant for the tests.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Clinical and biological features</title><p>Sixty RRMS patients participated in this study, of
which 30 subjects were selected 2-months after relapse.
Furthermore, 30 healthy subjects joined the study as the
control group. Patients and controls were sufficiently
matched in terms of age and sex. According to the
expression analysis results, there was no statistically
significant difference in sex and taking interferon and noninterferon drugs between patients and controls (P=0.619
and P=0.388, respectively). The biological characteristics
of two groups of patients (recurrent and recurrences for at
least two months) are shown in Table 2.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Biological and Clinical characteristics of patients and healthy
individuals</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">Control</th><th rowspan="1" colspan="1">Recurring patients</th><th rowspan="1" colspan="1">Two months after relapse patients</th></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">Number of subjects</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Males</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1"> Females</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">Drug</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Interferon</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1"> Non-interferon</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (Y)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Mean age</td><td rowspan="1" colspan="1">38.60 &#x000b1; 1.843</td><td rowspan="1" colspan="1">33.7 &#x000b1; 1.522</td><td rowspan="1" colspan="1">33.7 &#x000b1; 1.522</td></tr><tr><td align="left" rowspan="1" colspan="1"> Range </td><td rowspan="1" colspan="1">21-58</td><td rowspan="1" colspan="1">21-45</td><td rowspan="1" colspan="1">21-45</td></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr></tbody></table></table-wrap></sec><sec><title><italic>In-silico</italic> analysis</title><p>We provided a list including 178 genes that had overlap
between microRNAs and genes associated with multiple
sclerosis, and we presented these results using a VENN
Diagram (<xref rid="F1" ref-type="fig">Fig .1</xref>). Based on the enrichment of these genes,
we found that these genes are correlated with NF-&#x003ba;B
and TNF-&#x003b1; signaling pathways as vital pathways in MS.
(<xref rid="s1" ref-type="supplementary-material">Fig .S1</xref>, See Supplementary Online Information at <uri xlink:href="www.celljournal.org">www.
celljournal.org</uri>). Also, the enrichment results pointed to
the relationship between genes and MS in DisGeNET.
We reported an interaction between genes, pathways,
and microRNAs targeted genes in the cytoscape network
(<xref rid="F2" ref-type="fig">Fig .2</xref>). </p><fig position="float" id="F1"><label>Fig 1</label><caption><p>miRNA targets. Venn diagrams were employed to acquire the prediction of miRNAs that target
<italic>SP1</italic> and <italic>TNFSF4</italic> genes. The number of 178 indicated
the quantity of the selective miRNAs which target the genes.</p></caption><graphic xlink:href="Cell-J-24-403-g01" position="float"/></fig><fig position="float" id="F2"><label>Fig 2</label><caption><p>The network mapping. Interaction and correlation of mir and hub genes indicating
<italic>miR-330-5p, miR-106a,</italic> and <italic>miR-125b</italic> are associated
with <italic>SP1, TNFSF4</italic> genes in NF-&#x003ba;B/TNF-&#x003b1; pathway.</p></caption><graphic xlink:href="Cell-J-24-403-g02" position="float"/></fig></sec><sec><title>miR-330-5p is up-regulated in RRMS patients</title><p>miR-330-5p expression was assessed by qRT-PCR in two groups: The patients, including 30 patients with
recurrent presentations and 30 patients two months
after relapse (n=60) and healthy subjects (n=30). The
results indicated a significant growth (by 3-fold) in the
expression of this miRNA in patients (both recurrence
and two months after relapse) compared with healthy
subjects (P&#x0003c;0.0001 and P&#x0003c;0.0002, respectively,
<xref rid="F3" ref-type="fig">Fig .3A</xref>).</p></sec><sec><title>Down-regulation of miR-125b and miR-106a
expression in RRMS patients</title><p>To determine the potential roles of miR-125b and
miR-106a in RRMS patients, we investigated both
miRNAs&#x02019; expression levels in patients (two months
after relapse and recurrence) versus control individuals.
Our results demonstrated that miR-106a expression
was significantly down-regulated (by 0.5-fold) in
the recurrence and two months after relapse patients
compared with the control group (P&#x0003c;0.0001 and
P&#x0003c;0.006, respectively). Moreover, data demonstrated
that miR-125b was significantly diminished (by 0.7-
fold) in both recurrence and two months after relapse
patients (P&#x0003c;0.0001 and P&#x0003c;0.0005, respectively) and
probably plays an essential role in RRMS patients
(<xref rid="F3" ref-type="fig">Fig .3B, C</xref>).</p></sec><sec><title>Analysis of the expression level of <italic>TNFSF4</italic> and
<italic>SP1</italic></title><p>In this study, two potential targets of <italic>miR-330-5p, miR106a</italic> and
<italic>miR-125b</italic> were selected for further analyses. <italic>TNFSF4</italic>
and <italic>SP1</italic> were selected as mentioned in the methods. Our data indicated
decreased expression of <italic>SP1</italic> (by 0.5- fold) (P&#x0003c;0.0017 and
P&#x0003c;0.003, respectively). In contrast, <italic>TNFSF4</italic> expression was
increased significantly in recurrence and patients two months after relapse (by 3-fold)
(P&#x0003c;0.004 and P&#x0003c;0.02, respectively) compared with healthy (<xref rid="F3" ref-type="fig">Fig .3D, E</xref>).</p></sec><sec><title>Analysis of the expression relationship of miR-106a,
mir-125b, and miR-330 with selected targets</title><p>To assess the hypothesis&#x02019;s validity, we compared the expression level differences between
miR-106a and miR-125b in patients and control samples with the expression level
differences in <italic>TNFSF4 </italic>between patient and control samples. According to
data analysis, there was a significant inverse relationship between the reduced expression
levels of miR-106a and miR125b with the increase in <italic>TNFSF4</italic> expression.
The Pearson correlations for the association of miR-106 and miR-125b with
<italic>TNFSF4</italic> were equal to -0.4970 and -0.6284, respectively, and P values
showed significant relationships (P=0.0052 and P=0.0002, respectively, <xref rid="F4" ref-type="fig">Fig .4</xref>).</p><p>Moreover, the increase in miR-330 expression was inversely correlated with a decrease in
<italic>Sp1</italic> gene expression. The Pearson correlation r was -0.7280, while the
P&#x0003c;0.0001 showed the significance of the association (<xref rid="F4" ref-type="fig">Fig .4</xref>).</p><fig position="float" id="F3"><label>Fig 3</label><caption><p>Quantitative real-time polymerase chain reaction (PCR) analysis results. <bold>A. </bold>Relative
expression of <italic>miR-330-5p</italic>, <bold>B. </bold><italic>miR-106a,</italic>
and <bold>C.</bold><italic> miR125b</italic> in recurring patients and two months
after relapse patients and healthy individuals. Relative quantification for the
<italic>miR-330-5p</italic> (P&#x0003c;0.0001 and 0.0002, respectively),
<italic>miR-</italic>106a (P&#x0003c;0.0001 and P&#x0003c;0.006, respectively) and
<italic>miR-125b</italic> (P&#x0003c;0.0001 and P&#x0003c;0.0005, respectively) and
<bold>D. </bold><italic>TNFSF4</italic> (P&#x0003c;0.004 and P&#x0003c;0.02,
respectively), and <bold>E.</bold>
<italic>SP1</italic> (P&#x0003c;0.0017 and P&#x0003c;0.003, respectively) were
significantly different between patients and the control group. All Data were
presented as mean &#x000b1; SD (n=30 per group). Data were calculated using a one-way analysis
of variance (ANOVA) and Tukey&#x02019;s post hoc test.</p></caption><graphic xlink:href="Cell-J-24-403-g03" position="float"/></fig><fig position="float" id="F4"><label>Fig 4</label><caption><p>Graphs plotted from the Pearson correlation analysis showed a significant relationship between
microRNAs and their targets. This correlation between genes and their targets is
inverse. The Pearson correlation for associating miR-106 and <italic>TNFSF4</italic>
was equal to -0.497 and P&#x0003c;0.0052 and miR-125b with <italic>TNFSF4 </italic>was
equal to -0.6284 and P&#x0003c;0.0002. The Pearson correlation for miR-330 and
<italic>SP1</italic> was -0.7280, with a P&#x0003c;0.0001. All data were presented as
mean &#x000b1; SD (n=30 per group).</p></caption><graphic xlink:href="Cell-J-24-403-g04" position="float"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>MS&#x02019;s clinical pathophysiology is diverse to the extent that
despite the accessibility of therapeutics for the relapsing
type of MS, patients have clinical disease activity and
neurologic inability within months after disease onset.
Due to the need for more effective treatments, biomarkers
recruited for predicting inability and therapeutic response
assessment are desirable in managing patients (<xref rid="B28" ref-type="bibr">28</xref>). In MS,
dysregulation of miRNAs has been indicated in various
immune cells. Immense evidence has demonstrated
changes in miRNA expression in immune cells and
brain tissue of MS patients. Therefore, we explored the
correlation between MS progression and the expression
of miRNAs (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>In this study, the correlation of three miRNAs, such as miR-125b, miR-330-5p, and miR-106a
expression with MS disease, was investigated. We indicated significantly higher expression
of miR-330-5p in both RRMS groups than in healthy subjects. In contrast, a decrease was
revealed in the miR-125b and miR-106a expression in RRMS patients. According to the Choi et
al. (<xref rid="B30" ref-type="bibr">30</xref>) study, the expression of miR-330 increased during brain development and NSC (Neural
stem cells) differentiation. In a miRNA microarray analysis, it was indicated that miR-106a
was significantly reduced in MS patients (<xref rid="B31" ref-type="bibr">31</xref>). It has been proposed that the down-regulated
miR-125b expression could serve as a helpful noninvasive biomarker for Alzheimer&#x02019;s disease
(<xref rid="B32" ref-type="bibr">32</xref>). We investigated these three miRNAs&#x02019; potential roles via in-silico molecular enrichment
analysis, and we found a correlation between miRNA and gene roles in biological processes
involved in MS pathology. Notably, we indicated that miR-330- 5p, miR-106a, and miR-125b
were directly associated with the inflammation pathway. These data are supported our
hypothesis that there is a correlation between miR106a, miR-125b, and miR-330 in MSpatients
by targeting TNFSF4 and <italic>SP1</italic> in NF-&#x0043a;b/TNF-&#x003b1; pathway.</p><p>The regulation of immune system responses to nerve
cell myelin sheaths is a fundamental matter in MS
development. TNF-&#x003b1;/NF-&#x003ba;B signaling pathway has a
crucial role in autoimmune responses regulated by various
factors, and Sonar et al. indicated an association between
TNFSF and autoimmune disease (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>).</p><p>Another gene examined in this study is a transcription factor called SP1, which was
predicted to be targeted by miR-330 (<xref rid="B21" ref-type="bibr">21</xref>). SP1 is a transcription factor regulated by the
TNF-&#x003b1;/ NF-&#x003ba;B signaling pathway. This transcription factor is activated after binding to the
GC-box at NF&#x003ba;B binding sites. We found an association between SP1 and miR-106a, miR-125b,
and miR-330 in MS based on the bioinformatic analysis. Moreover, in-silico data have
demonstrated that SP1 could target the NF-&#x0043a;b/ TNF-&#x003b1; pathway. Based on the evidence, NF-&#x0043a;b
decreases through increasing miR-330 expression and subsequently with reduced expression of
SP1. Contrariwise, it can increase apoptosis in autoimmune diseases such as MS and
deteriorate the symptoms. Mao et al. (<xref rid="B21" ref-type="bibr">21</xref>) confirmed that miR-330 was downregulated and
inversely associated with SP1 expression. Also, they induced miR-330 expression by
transfection of miR-330 mimic, and the outcome was a reduction in expression levels of the
<italic>SP1</italic> gene, but the results of SP1-knockdown were contrary to previous.
Based on their research, miR-330 could target SP1 directly (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). </p><p>Recently, primary MS therapies have been based on the inhibition of the TNF-&#x003b1;/ NF-&#x003ba;B signaling pathway. Thus,
tumor factor &#x003b1;-necrosis factor (&#x003b1;) blockers are a treatment
of interest in many inflammatory and autoimmune
diseases (<xref rid="B35" ref-type="bibr">35</xref>). This therapeutic target can control the
demyelination of nerve cells in MS and its recurrence.
Therefore, regulatory inhibiting factors such as miR-330
might be acceptable candidates. However, miR-106a and
miR-125b are inhibitory candidates for treating MS and
other autoimmune conditions.
</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Our findings illustrated that low miR-106a and miR125b expression contributes to high
TNFSF4 expression, whereas increased miR-330 expression activates the TNF-&#x003b1; signaling
pathway by targeting and reducing the <italic>SP1 </italic>gene expression. Subsequently,
the activated TNF-&#x003b1; signaling pathway may lead to the initiation and progression of
autoimmune diseases such as MS.</p></sec><sec sec-type="supplementary-material"><title>Supplementary PDF</title><supplementary-material id="s1" position="float" content-type="local-data"><media xlink:href="Cell-J-24-403-s01.pdf" id="d64e696" position="anchor"/></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>There is no financial support and conflict of interest in
this study.
</p></ack><bio id="d64e701"><title>Authors&#x02019; Contributions</title><p>N.H., S.M.S.; Contributed to the conception and design.
N.H., F.Kh., F.N., B.N.; Contributed to all experimental work
and molecular experiments. F.Kh., P.R.; Contributed to the
conception, and design of the database and bioinformatic
analysis, statistical analysis, and data interpretation. N.H.;
Drafted the manuscript, which was revised by M.S.V.Sh.,
M.F.F.; Resources and methodology. M.S.; Conceptualization,
validation, visualization, and supervision. All authors read
and approved the final manuscript.</p></bio><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lassmann</surname><given-names>H</given-names></name>
</person-group><article-title>Multiple sclerosis pathology</article-title><source>Cold Spring Harb Perspect Med</source><year>2018</year><volume>8</volume><issue>3</issue><fpage>a028936</fpage><lpage>a028936</lpage><pub-id pub-id-type="pmid">29358320</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montalban</surname><given-names>X</given-names></name>
<name><surname>Hauser</surname><given-names>SL</given-names></name>
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Arnold</surname><given-names>DL</given-names></name>
<name><surname>Bar-Or</surname><given-names>A</given-names></name>
<name><surname>Comi</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Ocrelizumab versus placebo in primary progressive multiple sclerosis</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><issue>3</issue><fpage>209</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">28002688</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldenberg</surname><given-names>MM</given-names></name>
</person-group><article-title>Multiple sclerosis review</article-title><source>P T</source><year>2012</year><volume>37</volume><issue>3</issue><fpage>175</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">22605909</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stangel</surname><given-names>M</given-names></name>
<name><surname>Penner</surname><given-names>IK</given-names></name>
<name><surname>Kallmann</surname><given-names>BA</given-names></name>
<name><surname>Lukas</surname><given-names>C</given-names></name>
<name><surname>Kieseier</surname><given-names>BC</given-names></name>
</person-group><article-title>Towards the implementation of &#x02018;no evidence of disease activity&#x02019; in multiple sclerosis treatment: the multiple sclerosis decision model</article-title><source>Ther Adv Neurol Disord</source><year>2015</year><volume>8</volume><issue>1</issue><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">25584069</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patsopoulos</surname><given-names>NA</given-names></name>
</person-group><article-title>Genetics of multiple sclerosis: an overview and new directions</article-title><source>Cold Spring Harb Perspect Med</source><year>2018</year><volume>8</volume><issue>7</issue><fpage>a028951</fpage><lpage>a028951</lpage><pub-id pub-id-type="pmid">29440325</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kahl</surname><given-names>KG</given-names></name>
<name><surname>Kruse</surname><given-names>N</given-names></name>
<name><surname>Faller</surname><given-names>H</given-names></name>
<name><surname>Weiss</surname><given-names>H</given-names></name>
<name><surname>Rieckmann</surname><given-names>P</given-names></name>
</person-group><article-title>Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis</article-title><source>Psychoneuroendocrinology</source><year>2002</year><volume>27</volume><issue>6</issue><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">12084660</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>CM</given-names></name>
<name><surname>Oliveira</surname><given-names>SR</given-names></name>
<name><surname>Alfieri</surname><given-names>DF</given-names></name>
<name><surname>Flauzino</surname><given-names>T</given-names></name>
<name><surname>Kaimen-Maciel</surname><given-names>DR</given-names></name>
<name><surname>Sim&#x000e3;o</surname><given-names>ANC</given-names></name>
<etal/>
</person-group><article-title>Tumor necrosis factor alpha (TNF-&#x003b1;) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis</article-title><source>Inflamm Res</source><year>2019</year><volume>68</volume><issue>12</issue><fpage>1049</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">31559449</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fiedler</surname><given-names>SE</given-names></name>
<name><surname>George</surname><given-names>JD</given-names></name>
<name><surname>Love</surname><given-names>HN</given-names></name>
<name><surname>Kim</surname><given-names>E</given-names></name>
<name><surname>Spain</surname><given-names>R</given-names></name>
<name><surname>Bourdette</surname><given-names>D</given-names></name>
<etal/>
</person-group><article-title>Analysis of IL-6, IL-1&#x003b2; and TNF-&#x003b1; production in monocytes isolated from multiple sclerosis patients treated with disease modifying drugs</article-title><source>J Syst Integr Neurosci</source><year>2017</year><volume>3</volume><issue>3</issue><fpage>10</fpage><lpage>10</lpage></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>G</given-names></name>
<name><surname>Parkhurst</surname><given-names>CN</given-names></name>
<name><surname>Hayes</surname><given-names>S</given-names></name>
<name><surname>Gan</surname><given-names>WB</given-names></name>
</person-group><article-title>Peripheral elevation of TNF-&#x003b1; leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><issue>25</issue><fpage>10306</fpage><lpage>10311</lpage><pub-id pub-id-type="pmid">23733958</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>Y</given-names></name>
<name><surname>Dekens</surname><given-names>DW</given-names></name>
<name><surname>De Deyn</surname><given-names>PP</given-names></name>
<name><surname>Naud&#x000e9;</surname><given-names>PJ</given-names></name>
<name><surname>Eisel</surname><given-names>UL</given-names></name>
</person-group><article-title>Targeting of tumor necrosis factor alpha receptors as a therapeutic strategy for neurodegenerative disorders</article-title><source>Ab</source><year>2015</year><volume>4</volume><issue>4</issue><fpage>369</fpage><lpage>408</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>An</surname><given-names>J</given-names></name>
<name><surname>Ding</surname><given-names>S</given-names></name>
<name><surname>Hu</surname><given-names>X</given-names></name>
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Gu</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<etal/>
</person-group><article-title>Preparation, characterization and application of anti-human OX40 ligand (OX40L) monoclonal antibodies and establishment of a sandwich ELISA for autoimmune diseases detection</article-title><source>Int Immunopharmacol</source><year>2019</year><volume>67</volume><fpage>260</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">30562687</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Wanrooij</surname><given-names>EJ</given-names></name>
<name><surname>van Puijvelde</surname><given-names>GH</given-names></name>
<name><surname>de Vos</surname><given-names>P</given-names></name>
<name><surname>Yagita</surname><given-names>H</given-names></name>
<name><surname>van Berkel</surname><given-names>TJ</given-names></name>
<name><surname>Kuiper</surname><given-names>J</given-names></name>
</person-group><article-title>Interruption of the Tnfrsf4/Tnfsf4 (OX40/ OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2007</year><volume>27</volume><issue>1</issue><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">17068285</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>Y</given-names></name>
<name><surname>Tanaka</surname><given-names>R</given-names></name>
<name><surname>Yamamoto</surname><given-names>N</given-names></name>
<name><surname>Tanaka</surname><given-names>Y</given-names></name>
</person-group><article-title>Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production</article-title><source>AIDS Res Hum Retroviruses</source><year>2008</year><volume>24</volume><issue>3</issue><fpage>423</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">18327975</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ping</surname><given-names>D</given-names></name>
<name><surname>Boekhoudt</surname><given-names>G</given-names></name>
<name><surname>Zhang</surname><given-names>F</given-names></name>
<name><surname>Morris</surname><given-names>A</given-names></name>
<name><surname>Philipsen</surname><given-names>S</given-names></name>
<name><surname>Warren</surname><given-names>ST</given-names></name>
<etal/>
</person-group><article-title>Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><issue>3</issue><fpage>1708</fpage><lpage>1714</lpage><pub-id pub-id-type="pmid">10636866</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirano</surname><given-names>F</given-names></name>
<name><surname>Tanaka</surname><given-names>H</given-names></name>
<name><surname>Hirano</surname><given-names>Y</given-names></name>
<name><surname>Hiramoto</surname><given-names>M</given-names></name>
<name><surname>Handa</surname><given-names>H</given-names></name>
<name><surname>Makino</surname><given-names>I</given-names></name>
<etal/>
</person-group><article-title>Functional interference of Sp1 and NF-kappaB through the same DNA binding site</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><issue>3</issue><fpage>1266</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">9488441</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shende</surname><given-names>VR</given-names></name>
<name><surname>Kim</surname><given-names>SM</given-names></name>
<name><surname>Neuendorff</surname><given-names>N</given-names></name>
<name><surname>Earnest</surname><given-names>DJ</given-names></name>
</person-group><article-title>MicroRNAs function as cis- and trans-acting modulators of peripheral circadian clocks</article-title><source>FEBS Lett</source><year>2014</year><volume>588</volume><issue>17</issue><fpage>3015</fpage><lpage>3022</lpage><pub-id pub-id-type="pmid">24928439</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Tufekci</surname><given-names>KU</given-names></name>
<name><surname>Oner</surname><given-names>MG</given-names></name>
<name><surname>Genc</surname><given-names>S</given-names></name>
<name><surname>Genc</surname><given-names>K</given-names></name>
</person-group><source>MicroRNAs and multiple sclerosis.Autoimmune Diseases</source><publisher-name>Autoimmune Diseases</publisher-name><year>2011</year><fpage>2011</fpage><lpage>2011</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Honardoost</surname><given-names>MA</given-names></name>
<name><surname>Naghavian</surname><given-names>R</given-names></name>
<name><surname>Ahmadinejad</surname><given-names>F</given-names></name>
<name><surname>Hosseini</surname><given-names>A</given-names></name>
<name><surname>Ghaedi</surname><given-names>K</given-names></name>
</person-group><article-title>Integrative computational mRNA-miRNA interaction analyses of the autoimmune-deregulated miRNAs and wellknown Th17 differentiation regulators: An attempt to discover new potential miRNAs involved in Th17 differentiation</article-title><source>Gene</source><year>2015</year><volume>572</volume><issue>2</issue><fpage>153</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">26307197</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanctuary</surname><given-names>MR</given-names></name>
<name><surname>Huang</surname><given-names>RH</given-names></name>
<name><surname>Jones</surname><given-names>AA</given-names></name>
<name><surname>Luck</surname><given-names>ME</given-names></name>
<name><surname>Aherne</surname><given-names>CM</given-names></name>
<name><surname>Jedlicka</surname><given-names>P</given-names></name>
<etal/>
</person-group><article-title>miR-106a deficiency attenuates inflammation in murine IBD models</article-title><source>Mucosal Immunol</source><year>2019</year><volume>12</volume><issue>1</issue><fpage>200</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">30327532</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>BK</given-names></name>
<name><surname>Yoo</surname><given-names>HI</given-names></name>
<name><surname>Choi</surname><given-names>K</given-names></name>
<name><surname>Yoon</surname><given-names>SK</given-names></name>
</person-group><article-title>miR-330-5p inhibits proliferation and migration of keratinocytes by targeting Pdia3 expression</article-title><source>FEBS J</source><year>2015</year><volume>282</volume><issue>24</issue><fpage>4692</fpage><lpage>4702</lpage><pub-id pub-id-type="pmid">26402295</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mao</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
<name><surname>Lin</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Hu</surname><given-names>Z</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<etal/>
</person-group><article-title>microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells</article-title><source>Oncol Rep</source><year>2013</year><volume>30</volume><issue>1</issue><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">23670210</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sticht</surname><given-names>C</given-names></name>
<name><surname>De La Torre</surname><given-names>C</given-names></name>
<name><surname>Parveen</surname><given-names>A</given-names></name>
<name><surname>Gretz</surname><given-names>N</given-names></name>
</person-group><article-title>miRWalk: An online resource for prediction of microRNA binding sites</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><issue>10</issue><fpage>e0206239</fpage><lpage>e0206239</lpage><pub-id pub-id-type="pmid">30335862</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pi&#x000f1;ero</surname><given-names>J</given-names></name>
<name><surname>Ram&#x000ed;rez-Anguita</surname><given-names>JM</given-names></name>
<name><surname>Sa&#x000fc;ch-Pitarch</surname><given-names>J</given-names></name>
<name><surname>Ronzano</surname><given-names>F</given-names></name>
<name><surname>Centeno</surname><given-names>E</given-names></name>
<name><surname>Sanz</surname><given-names>F</given-names></name>
<etal/>
</person-group><article-title>The DisGeNET knowledge platform for disease genomics: 2019 update</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>D1</issue><fpage>D845</fpage><lpage>D855</lpage><pub-id pub-id-type="pmid">31680165</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jassal</surname><given-names>B</given-names></name>
<name><surname>Matthews</surname><given-names>L</given-names></name>
<name><surname>Viteri</surname><given-names>G</given-names></name>
<name><surname>Gong</surname><given-names>C</given-names></name>
<name><surname>Lorente</surname><given-names>P</given-names></name>
<name><surname>Fabregat</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>The reactome pathway knowledgebase</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>D1</issue><fpage>D498</fpage><lpage>D503</lpage><pub-id pub-id-type="pmid">31691815</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shannon</surname><given-names>P</given-names></name>
<name><surname>Markiel</surname><given-names>A</given-names></name>
<name><surname>Ozier</surname><given-names>O</given-names></name>
<name><surname>Baliga</surname><given-names>NS</given-names></name>
<name><surname>Wang</surname><given-names>JT</given-names></name>
<name><surname>Ramage</surname><given-names>D</given-names></name>
<etal/>
</person-group><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res</source><year>2003</year><volume>13</volume><issue>11</issue><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Q</given-names></name>
</person-group><article-title>The critical importance of epigenetics in autoimmunity</article-title><source>J Autoimmun</source><year>2013</year><volume>41</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">23375849</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fathullahzadeh</surname><given-names>S</given-names></name>
<name><surname>Mirzaei</surname><given-names>H</given-names></name>
<name><surname>Honardoost</surname><given-names>MA</given-names></name>
<name><surname>Sahebkar</surname><given-names>A</given-names></name>
<name><surname>Salehi</surname><given-names>M</given-names></name>
</person-group><article-title>Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia</article-title><source>Cancer Gene Ther</source><year>2016</year><volume>23</volume><issue>10</issue><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">27659777</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hauser</surname><given-names>SL</given-names></name>
<name><surname>Bar-Or</surname><given-names>A</given-names></name>
<name><surname>Comi</surname><given-names>G</given-names></name>
<name><surname>Giovannoni</surname><given-names>G</given-names></name>
<name><surname>Hartung</surname><given-names>HP</given-names></name>
<name><surname>Hemmer</surname><given-names>B</given-names></name>
<etal/>
</person-group><article-title>Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><issue>3</issue><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">28002679</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Regev</surname><given-names>K</given-names></name>
<name><surname>Healy</surname><given-names>BC</given-names></name>
<name><surname>Khalid</surname><given-names>F</given-names></name>
<name><surname>Paul</surname><given-names>A</given-names></name>
<name><surname>Chu</surname><given-names>R</given-names></name>
<name><surname>Tauhid</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Association between serum micrornas and magnetic resonance imaging measures of multiple sclerosis severity</article-title><source>JAMA Neurol</source><year>2017</year><volume>74</volume><issue>3</issue><fpage>275</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">28114622</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>I</given-names></name>
<name><surname>Woo</surname><given-names>JH</given-names></name>
<name><surname>Jou</surname><given-names>I</given-names></name>
<name><surname>Joe</surname><given-names>EH</given-names></name>
</person-group><article-title>PINK1 deficiency decreases expression levels of mir-326, mir-330, and mir-3099 during brain development and neural stem cell differentiation</article-title><source>Exp Neurobiol</source><year>2016</year><volume>25</volume><issue>1</issue><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">26924929</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cox</surname><given-names>MB</given-names></name>
<name><surname>Cairns</surname><given-names>MJ</given-names></name>
<name><surname>Gandhi</surname><given-names>KS</given-names></name>
<name><surname>Carroll</surname><given-names>AP</given-names></name>
<name><surname>Moscovis</surname><given-names>S</given-names></name>
<name><surname>Stewart</surname><given-names>GJ</given-names></name>
<etal/>
</person-group><article-title>MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><issue>8</issue><fpage>e12132</fpage><lpage>e12132</lpage><pub-id pub-id-type="pmid">20711463</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>L</given-names></name>
<name><surname>Yu</surname><given-names>JT</given-names></name>
<name><surname>Liu</surname><given-names>QY</given-names></name>
<name><surname>Tan</surname><given-names>MS</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Hu</surname><given-names>N</given-names></name>
<etal/>
</person-group><article-title>Circulating miR-125b as a biomarker of Alzheimer&#x02019;s disease</article-title><source>J Neurol Sci</source><year>2014</year><volume>336</volume><issue>1-2</issue><fpage>52</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">24139697</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sicotte</surname><given-names>NL</given-names></name>
<name><surname>Voskuhl</surname><given-names>RR</given-names></name>
</person-group><article-title>Onset of multiple sclerosis associated with anti-TNF therapy</article-title><source>Neurology</source><year>2001</year><volume>57</volume><issue>10</issue><fpage>1885</fpage><lpage>1888</lpage><pub-id pub-id-type="pmid">11723281</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sonar</surname><given-names>S</given-names></name>
<name><surname>Lal</surname><given-names>G</given-names></name>
</person-group><article-title>Role of tumor necrosis factor superfamily in neuroinflammation and autoimmunity</article-title><source>Front Immunol</source><year>2015</year><volume>6</volume><fpage>364</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">26257732</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kemanetzoglou</surname><given-names>E</given-names></name>
<name><surname>Andreadou</surname><given-names>E</given-names></name>
</person-group><article-title>CNS demyelination with TNF-&#x003b1; blockers</article-title><source>Curr Neurol Neurosci Rep</source><year>2017</year><volume>17</volume><issue>4</issue><fpage>36</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">28337644</pub-id></element-citation></ref></ref-list></back></article>
